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Background
DNA vaccines are weakly immunogenic in humans and
one way of increasing their immunogenicity is by adminis-
tering the vaccines using electroporation (EP). This techni-
que increases the uptake of the DNA into the cell by
producing an electrical field which makes the cellular
membrane more permeable. In the ongoing trial, we are
using the ICHOR TriGrid Delivery system (TDS-IM) to
administer bilateral injections of an HIV pDNA vaccine by
EP into the medial deltoid muscles.
Methods
We assessed the acceptability and tolerability of Electro-
poration among 37 volunteers who received two injections
by EP/IM at their first vaccination time point by adminis-
tering a questionnaire after the procedure. Tolerability was
assessed at 4 time points: i) before the vaccine was
injected, ii) at the time of electrical stimulation, iii) 10
minutes and iv) 30 minutes after the procedure. The pain
was graded as none, light, uncomfortable, intense, severe
or very severe.
We also sought their opinion on acceptability of the
procedure as a method of vaccine administration.
Results
Of the 37 volunteers, 45.9% felt no pain at time before
vaccine was injected. At time of electrical stimulation,
59.5% felt light pain, 29.7 felt uncomfortable and 10.8%
felt intense pain. Ten minutes after the procedure, 56.8%
felt light pain, 29.7 felt uncomfortable and 13.5% felt no
pain. Thirty minutes after procedure, 70.3% felt light pain,
13.5% felt uncomfortable and 2.7% felt intense pain but
this was associated with multiple device applications to
the site prior to achieving administration. Majority of the
volunteers (94.6%) thought that vaccination by EP would
be acceptable if the vaccine protected people from acquir-
ing HIV and contributed to scientific knowledge on
vaccine administration.
Conclusion
Electroporation among African volunteers in this trial is
tolerable and acceptable. EP may be considered in future
for the administration of HIV vaccines.
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